AOL.co.uk14d
Starmer labels Tories ‘coalition of blockers’ as he defends growth plan at PMQs
Sir Keir Starmer has claimed the Conservatives are the “coalition of blockers” as he defended his Government’s growth proposals and employment law reforms. The Prime Minister highlighted ...
Medscape14d
Azilsartan (EDARBI): A New Angiotensin Receptor Blocker (ARB) for Hypertension
Figure 1. Chemical Structure of Azilsartan Medoxomil (PubChem CID: 11238823) Figure 2. Chemical Structure of Azilsartan (PubChem CID: 9825285) ...
Business Standard20d
Canada PR: 4 new permanent residency pathways to be introduced in 2025
Want to apply for Canada PR? The country is set to introduce four new permanent residency (PR) pathways in 2025, even as the government plans to reduce its PR targets from 485,000 to 465,000, ...
Medscape23d
Combination Angiotensin Receptor Blocker/Hydrochlorothiazide as Initial Therapy in the Treatment of Patients With Severe Hypertension
The authors hypothesized that initial treatment with a combination angiotensin receptor blocker/diuretic agent would be safe and more effective than initial treatment with a single agent for these ...
C&EN27d
Sulfated and Glucuronidated Conjugates of 3-(4-Hydroxy-3-methoxyphenyl) Propionic Acid Can Promote NO Production by Elevated Ca
Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School of Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan ...
WCVB Channel 5 Boston28d
New 'pathway program' offers possible solution to local doctor shortage
GOVERNOR MAURA HEALEY RECENTLY SIGNED IT INTO LAW AS THE PHYSICIAN PATHWAY ACT. A BUSY PRIMARY CARE DOCTOR TAKES CARE OF 1500 TO UP TO 2000 PATIENTS, SO JUST EVEN ONE PERSON GO INTO A COMMUNITY ...
C&EN29d
Comment on “Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy”
Université de Bourgogne, U1231 INSERM, CTM, Equipe DesCarTes, UFR Sciences de Santé, 7 Bd Jeanne d’Arc, 21078 Dijon Cedex, France ...
UroToday29d
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial.
The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus ...